Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VRTX.MX
Strong BuyVertex Pharmaceuticals Incorporated · Healthcare · United States · $140.6B · Avg Vol: $79K/d
94
StockRankGet insider-trade alerts
Q
79
V
40
M
79
P/E (TTM)
32.3x
ROE
23.5%
D/E
0.1x
Dividend %
—
COMPANY DESCRIPTION
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
FINANCIAL SUMMARY (MXN)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 152.1B | 168.1B | 187.7B | 204.4B | 10.4% | 214.3B | 224.7B | 248.9B | 10.4% |
| EPS (MXN) | 220.85 | 239.24 | -35.42 | 263.25 | 6.0% | 292.70 | — | — | — |
| Shares | 257.0M | 257.7M | 256.9M | 254.0M | -1.2% | 253.5M | — | — | — |
| Debt | 15.3B | 13.8B | 29.7B | 34.6B | 31.2% | 33.7B | — | — | — |
| Equity | 236.9B | 299.4B | 279.4B | 317.8B | 10.3% | — | — | — | — |
| Op CF | 70.3B | 60.2B | -8.4B | 61.8B | -4.2% | 73.1B | — | — | — |
| Inv CF | -5.5B | -53.5B | -64.2B | -16.1B | — | — | — | — | — |
| Fin CF | -1.2B | -9.6B | -25.5B | -38.5B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+12.0%
SMA 50SMA 200
Close
$547.04
RSI (14)
77.6
52W High
$552.62
From 52W High
1.0%
SCORE BREAKDOWN
Quality
79
ROIC
23.2%93.6
ROE
23.5%91.6
GP/Assets
27.0%59.7
Op. Margin
38.1%95.6
FCF/Assets
14.8%92.8
Piotroski
669.5
Int. Cover
50.0x89.3
D/E Ratio
0.10x62.6
Current Ratio
3.19x56.8
Value
40
P/E (TTM)
32.3x36.1
EV/EBITDA
27.5x21.4
P/FCF
37.1x36.5
P/B
0.4x97.9
P/S
11.2x25.4
Div Yield
—N/A
Momentum
79
52W High %
99%98.8
RS 6M
19%79.6
SMA 50/200
1.06x71.6
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
7%45.5
FUNDAMENTALS
Market Cap
$140.6B
P/E (Forward)
—
Gross Margin
55.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VRTX.MX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VRTX.MX | Vertex Pharmaceuticals Incorporated(you) | $140.6B | 94 | Strong Buy |
| RGO.DE | Regeneron Pharmaceuticals, Inc. | $84.9B | 85 | Strong Buy |
| 6160.HK | BeOne Medicines AG | $42.1B | 92 | Strong Buy |
| UCB.BR | UCB SA | $47.8B | 84 | Strong Buy |
| ARGX.BR | argenx SE | $64.5B | 75 | Buy |
| INCY | Incyte Corporation | $25.2B | 96 | Strong Buy |
| CSL.AX | CSL Limited | $38.0B | 79 | Buy |
| 2269.HK | WuXi Biologics (Cayman) Inc. | $26.5B | 82 | Strong Buy |
| GMAB.CO | Genmab A/S | $20.8B | 86 | Strong Buy |
| JAZZ | Jazz Pharmaceuticals plc | $15.9B | 91 | Strong Buy |
Peer medians: ROE 1.9% · P/E 23.9x · Gross margin 52.1%